Dual-agent photodynamic therapy using methylene blue and zinc oxide nanoparticles: sequential illumination enhances apoptotic response in melanoma. (2025)

Peer-Reviewed Study · Esfahani HS, Ghasemi M, Khorsandi K, Hosseinzadeh R, Hosseinzadeh G, Shahidi FK · October 23, 2025

Esfahani HS et al., 2025-10-23: Iranian 2025 in-vitro study of dual-agent photodynamic therapy with methylene blue and zinc oxide nanoparticles under sequential illumination in melanoma cells, reporting enhanced apoptotic response.

This study aims to enhance the efficacy of PDT in melanoma treatment by employing a dual wavelength-assisted approach using Methylene Blue (MB) and zinc oxide nanoparticles (ZnO NPs).

452

Esfahani HS et al., 2025-10-23: Iranian 2025 in-vitro study of dual-agent photodynamic therapy with methylene blue and zinc oxide nanoparticles under sequential illumination in melanoma cells, reporting enhanced apoptotic response. C8 Iran (Yazd/Islamic Azad University groups). Study type: cell-line study (melanoma), no patients. Methylene blue concentration, light wavelength and dose not in the abstract captured. Comparator: methylene blue PDT alone and controls. Funder/conflicts: authors declare no competing interests. Journal Lasers Med Sci 40(1):452. Bearing PARTLY: laboratory only. Study type: lab.